Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease

Publisher： John Wiley & Sons Inc

E-ISSN： 1440-1746|33|3|631-637

ISSN： 0815-9319

Source： JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.33, Iss.3, 2018-03, pp. : 631-637

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high‐risk patients – a POCER study analysis

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 7, 2015-10 ,pp. : 867-879

John Wiley & Sons Inc

Access to resources Recommend Favorite

Biologic dose tailoring in Crohn disease

By  

INTERNAL MEDICINE JOURNAL, Vol. 45, Iss. 2, 2015-02 ,pp. : 170-177

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of infliximab with adalimumab in 827 biologic‐naïve patients with Crohn's disease: a population‐based Danish cohort study

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 596-604

John Wiley & Sons Inc

Access to resources Recommend Favorite

A practical, evidence-based guide to the use of adalimumab in Crohn’s disease

By Rubin David T.   Panaccione Remo   Chao Jingdong   Robinson Anne M.  

Current Medical Research and Opinion, Vol. 27, Iss. 9, 2011-09 ,pp. : 1803-1813

Informa Healthcare

Access to resources Recommend Favorite

Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease – authors' reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 2, 2015-07 ,pp. : 241-241

John Wiley & Sons Inc

Access to resources Recommend Favorite